Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study-Reference-Cited by-同舟云学术

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Published:2017-01 Issue:1 Volume:18 Page:88-99
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Passamonti Francesco,Griesshammer Martin,Palandri Francesca,Egyed Miklos,Benevolo Giulia,Devos Timothy,Callum Jeannie,Vannucchi Alessandro M,Sivgin Serdar,Bensasson Caroline,Khan Mahmudul,Mounedji Nadjat,Saydam Guray

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia;Vannucchi;Intern Emerg Med,2010

2. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes;Vardiman;Blood,2009

3. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders;Levine;Nat Rev Cancer,2007

4. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study;Tefferi;Leukemia,2013

5. How we identify and manage patients with inadequately controlled polycythemia vera;Reiter;Curr Hematol Malig Rep,2016

Cited by 207 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera;Journal of Clinical Medicine;2024-08-22

2. Equitable access to polycythemia vera treatments: addressing reimbursement disparities in Europe;Annals of Hematology;2024-07-24

3. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

4. Polycythemia vera: past, present and future;Leukemia & Lymphoma;2024-06-13

5. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia;American Journal of Hematology;2024-06-06